392 related articles for article (PubMed ID: 17452303)
1. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report.
Sirimongkolrat T; Premasathian N; Vongwiwatana A; Limsrichamrern S; Cheunsuchon B; Vasuvattakul S
Transplant Proc; 2008 Sep; 40(7):2440-1. PubMed ID: 18790261
[TBL] [Abstract][Full Text] [Related]
4. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab.
Westphal S; Hansson S; Mjörnstedt L; Mölne J; Swerkersson S; Friman S
Transplant Proc; 2006 Oct; 38(8):2659-60. PubMed ID: 17098031
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for idiopathic membranous nephropathy: who can benefit?
Ruggenenti P; Chiurchiu C; Abbate M; Perna A; Cravedi P; Bontempelli M; Remuzzi G
Clin J Am Soc Nephrol; 2006 Jul; 1(4):738-48. PubMed ID: 17699281
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
Rodríguez-Ferrero M; Ampuero J; Anaya F
Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
8. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation.
Schwarz A; Krause PH; Offermann G; Keller F
Transplantation; 1994 Sep; 58(6):650-4. PubMed ID: 7940683
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for post-transplant recurrences of FSGS.
Bayrakci US; Baskin E; Sakalli H; Karakayali H; Haberal M
Pediatr Transplant; 2009 Mar; 13(2):240-3. PubMed ID: 18822107
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis.
Gossmann J; Scheuermann EH; Porubsky S; Kachel HG; Geiger H; Hauser IA
Transpl Int; 2007 Jun; 20(6):558-62. PubMed ID: 17433091
[TBL] [Abstract][Full Text] [Related]
11. Membranous nephropathy: recurrence after kidney transplantation.
Marcen R; Mampaso F; Teruel JL; Rivera ME; Orofino L; Navarro-Antolin J; Ortuño J
Nephrol Dial Transplant; 1996 Jun; 11(6):1129-33. PubMed ID: 8671981
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
13. Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab.
Weclawiak H; Ribes D; Guilbeau-Frugier C; Touchard G; Kamar N; Mehrenberger M; Modesto A; Rostaing L
Clin Nephrol; 2008 May; 69(5):373-6. PubMed ID: 18538101
[TBL] [Abstract][Full Text] [Related]
14. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation.
Dello Strologo L; Guzzo I; Laurenzi C; Vivarelli M; Parodi A; Barbano G; Camilla R; Scozzola F; Amore A; Ginevri F; Murer L
Transplantation; 2009 Aug; 88(3):417-20. PubMed ID: 19667947
[TBL] [Abstract][Full Text] [Related]
15. New insights into the pathophysiology of idiopathic nephrotic syndrome.
Bruneau S; Dantal J
Clin Immunol; 2009 Oct; 133(1):13-21. PubMed ID: 19410518
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.
Vischini G; Cudillo L; Ferrannini M; Di Daniele N; Cerretti R; Arcese W
J Nephrol; 2009; 22(1):160-3. PubMed ID: 19229832
[TBL] [Abstract][Full Text] [Related]
17. Membranous glomerulonephritis (MGN) in transplanted kidneys: morphologic investigation on 256 renal allografts.
Monga G; Mazzucco G; Basolo B; Quaranta S; Motta M; Segoloni G; Amoroso A
Mod Pathol; 1993 May; 6(3):249-58. PubMed ID: 8346172
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient.
Gallon L; Chhabra D
Am J Transplant; 2006 Dec; 6(12):3017-21. PubMed ID: 17294527
[TBL] [Abstract][Full Text] [Related]
19. Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab.
Kuppachi S; Chander P; Yoo J
J Nephrol; 2009; 22(4):561-4. PubMed ID: 19662613
[TBL] [Abstract][Full Text] [Related]
20. Focal segmental glomerulosclerosis after membranous glomerulonephritis in remission: temporal diversity of glomerulopathy after bone marrow transplantation.
Chan GS; Chim S; Fan YS; Chan KW
Hum Pathol; 2006 Dec; 37(12):1607-10. PubMed ID: 17020780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
